Ipsen Regulated Information | Investor Relations

Regulated Information

Filter

Period

Filter by

recent search

Showing: 105 of 107 Regulated Information

Ipsen – Consolidated Financial Statements – 2022
Ipsen – Consolidated Financial Statements – 2022


IPSEN: Monthly information relative to the total number of voting rights  and shares composing the share capital
IPSEN: Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital


Ipsen – Half year statement – 2022 12 31
Ipsen – Half year statement – 2022 12 31

This article or press release has no online content. Please download the associated documents for more information.


Voting rights on 31 December 2022
Voting rights on 31 December 2022

This article or press release has no online content. Please download the associated documents for more information.


Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva

PARIS, FRANCE, 23 December 2022 – The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation (heterotopic ossification) in people…


1 13 14 15 16 17 18 19 22